Darlene Coleman Deecher, Ph.D.
2570 Keiser Rd, Quakertown, PA 18951
215-529-7935 (H); 484-919-7253 (M)
Profile available: http://www.linkedin.com/pub/b/36/b77
Career Overview: Comprehensive pharmaceutical research & development experience including target identification, drug
discovery, preclinical safety assessment and pk/efficacy relationships, project team lead, project management, regulatory
filings (Global Submissions), biomarker strategy, clinical design (SAD, MAD, PH 2 & 3; learn & confirm team member), product
launch activities (Advisory boards, Educational Training, Scientific Platform, competitive landscape surveillance) & Global
Business Development. Recognized ability to execute and deliver under stringent timelines with extensive leadership and
EDUCATION: Temple University, Philadelphia, PA (Quality Assurance/Regulatory Affairs)-in progress
Syracuse University, Syracuse, NY (Toxicology/Pharmacology) - PhD
SUNY Albany, Albany, NY; (Science Education) - MS
Syracuse University, Utica, NY; (Biology) - BS
Mohawk Valley College, Utica, NY; (Science) - AS
2008 Director Wyeth Research, Women’s Health, Collegeville, PA
Management of all aspects of drug discovery and specific development activities related to advanced projects in the
menopausal health area including collaborations, licensing opportunities, competitive strategy, budgeting, laboratory &
personnel management, short & long term strategic planning. Nominated by Wyeth Executive Committee to
Participate in Advanced Leadership Program for Future Leader Women Leaders. Awarded “Women Scientist of the
Year for Contributions to Women’s Health. Selected as task force member to develop content and presentations for
workshop on drug discovery and data interpretation of preclinical in vivo model utility and translational research for
Learn Teams (Ph 1 & 2).
2004 Associate Director Wyeth Research, Women’s Health, Collegeville, PA
Direct research in the area of neuroendocrinology and menopausal health. Manage 13 direct reports in biological
research. Team leader for an advanced discovery teams directing a team of biologist, chemistry, safety and early
clinical scientists. Discovery liaison for a phase III clinical compound, active member of a global development & brand
team, regulatory strategy team and a menopausal health strategy learn team as well as a member of commercial
consultant committee on opportunities assessment and in-licensing. Co-team leader on target for pain management in
cross functional therapeutic opportunity. Selected top 5% of performers within R & D and advanced into a leadership
program to allow for networking and leadership training. Developed a workshop to train Wyeth Discovery Scientists in
the “New Way of Working in Drug Discovery. Developed content and traveled to all Wyeth discovery sites and trained
~200 senior level chemists, biologists and safety scientists.
2003 Principal Scientist-Pharm III. Wyeth Research, Endocrinology, Collegeville, PA
Team leader for 2 discovery projects entering the pipeline. Discovery Team leader for advanced compound in Phase
III. Managed 10 direct reports and co-team leader of discovery project leading a large team of medicinal chemists,
pharmacologists and drug metabolism and safety scientists (~35 members). Active member of global development &
brand teams including strategy team for menopausal health and neuroscience-related directives. Selected as a
committee member to redesign processes and guidelines for the new way of working in drug discovery at Wyeth.
Required Executive governance approval.
2002 Principal Scientist-Pharm II. Wyeth Research, Endocrinology, Collegeville, PA
Team leader- Biology, Discovery Team in an area of menopausal health. Managed 8 direct reports & a team of 20+
drug discovery scientists to advance a project forward to development track. Included all aspects of small molecule
discovery (SAR, in vivo testing, pk/efficacy relationships, preclinical safety assessment)
2001 Principal Scientist-Pharm 1. Wyeth Research, Endocrinology, Collegeville, PA
Team leader Biology, Menopausal Health Exploratory Team. Managed 6 direct reports in all aspects of discovery
research. Responsible for leading biology and chemistry efforts to advance team to next milestone.
2000 Senior Research Scientist-Pharm III. Wyeth, Molecular Biology, Radnor, PA
Special Assignment- assay development of G-protein coupled receptor target for high throughput format,
implementation of screening, coordinate biology and chemistry efforts on the project for lead optimization. Received
Wyeth Recognition Award for execution of this assignment.
1998 Senior Research Scientist-Pharm II. Wyeth Research, Molecular Biology, Radnor, PA
Exploratory/target ID research-estrogen action in the CNS-Ca2+ mobilization, primary rat cortical and hippocampal
cultures (mixed, glial, neuronal), immunocytochemistry, protein characterization using traditional biochemistry
1997 Senior Research Scientist. Wyeth Research, Molecular Biology, Radnor, PA
Exploratory research efforts focused on the role of estrogen action in the CNS. Responsibilities include support of
Molecular Biologists in designing and implementing in-vitro and in-vivo assays for identification of targets related to
estrogen action in the brain. The same assay systems, as mentioned below, with the addition of luciferase reporter,
cytotoxicity and apoptotic assay.
1994 Senior Research Scientist. Wyeth Research, Peptide Pharmacology, Radnor, PA
Receptor Pharmacologist in charge of assay development for new lead generation of a GPCR target determined by
WHRI directives. Responsibilities include assay development (cell and tissue based assay-radioligand binding, signal
transduction; reporter assays, Elisa, solid phase, adenovirus infections, transfections) for medium and high throughput
efforts. Coordinated high throughput leads, secondary testing and chemistry efforts on therapeutic target.
1992 Senior Pharmacologist. Abbott Laboratories, New Lead Discovery, Abbott Park, IL
Coordinator: Receptor Pharmacologist in charge of identification of Neuroscience targets, development and
implementation of all high throughput screens. Responsibilities include coordinator of Neuroscience Division’s assay
development needs, prioritization of targets for development, chemistry initiatives and follow through, supervision of
Associate Pharmacologists and maintenance of a basic research program (therapeutic targets-Neuroscience).
Specialty: Assay development (receptors (GPCRs and intracellular), enzymes, channels and second messengers
(cAMP, IP3), miniaturization and screening (medium and high throughput). Requirements: receptor pharmacology, cell
culture, signal transduction, in vitro and in vivo experience.
1990 Postdoctorate Fellow. Albany Medical College, Dept. Pharmacology, Albany, NY
Characterization of novel opiate and serotonin-like compounds using receptor pharmacology techniques for GPCRs.
Radioligand binding, second messenger assays, autoradiography, cell culture and molecular techniques.
1989 Postdoctorate Fellow. NYSAES Cornell University, Geneva, NY
Molecular interactions of neurotoxic agents on voltage-dependent sodium channels in mammalian CNS. Techniques:
radiosodium flux and radioligand binding bioassays using neuronal homogenates.
PRIMARY RESEARCH PUBLICATIONS (refereed)
DC Deecher, X. Chen, J Roman, S Cosmi (2009). Evaluation of Age and Ovariectomy time on Temperature dysregulation in
the Ovariectomized Rat. Endocrinology in preparation.
DC Deecher, S Cosmi, L Leventhal, R Winneker (2009). Norepinephrine reuptake inhibition alleviated temperature
dysregulation in the Ovariectomized Rat. Endocrinology in preparation.
DC Deecher, S Cosmi, E Koury, P Alfinito, R Winneker (2009) Evaluation of norepinephrine reuptake inhibition and serotonin
receptor2A interaction in temperature regulation in the Ovariectomized Rat. Neuroendocrinology in preparation.
EJ Koury, PD Alfinito, P. Zhang, C. Stephens, J, Yao, D. Yates and DC Deecher (2009). Comparative evaluation of
reboxetine's pharmacokinetic properties with biomarker endpoints in female cynamologous monkeys. Brain Research in
KD Dave, JA Bray, DC Deecher (2009) Administration of 17β-estradiol to ovariectomized mice reduces anxiety in the marble
burying model. Hormones & Behavior in preparation.
DC Deecher, R. Mastroeni C Maddage, P. Alfinito, A. Pawlyk (2009) Development of a Female Rat Model of Sexual Low
Motivation for Subchronic Dosing Administration. Animal Behavior in preparation
DC Deecher, C Maddage, X. Chen, S Cosmi, A Pawlyk, P. Alfinito. (2009) Development of a Female Rat Model of Sexual Low
Motivation. Hormones & Behavior in preparation.
DC Deecher, C Maddage, A. Pawlyk, K Dave, X. Chen, R. Mastroeni, S Cosmi, P. Alfinito. (2009) Oxytocin improves sexual
function in a Female Rat Model of Sexual Low Motivation. Neuropharm in preparation.
A Pawlyk, R. Mastroneni, PD Alfinito, S Cosmi, DC Deecher (2009) Imixolan Exerts Multiple Effects on Temperature
Regulation in Ovariectomized Rats. JPET in preparation.
PD Alfinito, X Chen, R Mastroeni, AC Pawlyk & DC Deecher (2009) Estradiol increases catecholamine levels in the
hypothalamus of ovariectomized rats during the dark-phase. European J Pharm in review
GD Heffernan, RD Coghlan, ES Manas, RE McDevitt, Y Li, PE. Mahaney, AJ Robichaud, EJ Trybulski, PD Alfinito, JA Bray,
SA Cosmi, GH Johnston, T Kenney, E Koury & DC Deecher (2009) Dual acting norepinephrine reuptake inhibitors and 5-
HT2A receptor antagonists: Identification, synthesis and activity of novel 4-dialkylaminoethyl-3-(phenylsulfonyl)-1H-indoles.
Bioorganic & Medicinal Chemistry in press
S Cosmi, A Pawlyk, PD Alfinito, J Roman, DC Deecher (2009) Telemetric Measurement Of Tail-Skin and Core Body
Temperature in Ovariectomized Rat. J NeuroSci Methods 178(2):270-275.
EJ Koury, AC Pawlyk, CL Smolenski, TJ Berrodin, S Nagpal & DC Deecher (2009) Characterization of Ligands for Thyroid
Receptor Subtypes and their Interactions with Co-Regulators. Steroids 74(2):270-276.
P Zhang, EA Terefenko, C McComas, P Mahaney, A Vu, E Trybulski, E Koury, G Johnston, J Bray, DC Deecher (2008)
Synthesis and Activity of Novel 1- or 3-(3-Amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as Selective
Norepinephrine Reuptake Inhibitors. Bioorganic Med Chem Letters 18:6067-6070.
PD Alfinito, X Chen, J Atherton, S Cosmi, DC Deecher (2008) ICI 182,780 Penetrates Brain and Hypothalamus Tissue and
has Antiestrogenic and Estrogenic Actions in the Brain Following Systemic Dosing. Endocrinology 149 (10):5219-5226.
AC Pawlyk, PD Alfinito, DC Deecher (2008) Effect of 17t -Ethinyl Estradiol on Active Phase Rapid Eye Movement Sleep
Microarchitecture. European J Pharm 591(1-3):315-8.
CC McComas, A Vu, PE Mahaney, S Cohn, A Fensome, MA Marella, L Nogle, EJ Trybulski, F Ye, P Zhang, P Alfinito, J Bray,
G Johnston, E Koury, DC Deecher (2008) Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: A new
class of selective norepinephrine reuptake inhibitors Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: A
new class of selective norepinephrine reuptake inhibitors. Bioorganic Med Chem Letters 18(18):4929-31.
P Mahaney, LK Gavrin, EJ Trybulski, AT. Vu, GP Stack, S Cohn, JP Sabatucci, F Ye,J Belardi, A Santilli, J Leiter, GH
Johnston, JA Bray,† K Burroughs, S Cosmi, L Leventhal,† E Koury, Y Zhang, C Mugford, DM Ho, S Rosenzweig-Lipson, B
Platt & DC Deecher (2008) SAR of the Cycloalkanol Ethylamine Scaffold: Discovery of Selective Norepinephrine
Reuptake Inhibitors –J Med Chem 51(13):4038-49
A Pawlyk, P Alfinito, G Johnston & DC Deecher (2008) Subchronic 17 -ethinyl estradiol differentially affects subtypes of sleep
and wakefulness in ovariectomized rats. Hormones & Behavior 53:217-224.
JH. Mason, DC Deecher, RJ Richmond, G Stack, PE Mahaney, EJ Trybulski, RC Winneker & RD. Blakely (2007)
Desvenlafaxine succinate (DVS) identifies novel antagonist binding determinants in the human norepinephrine transporter.
J Pharm Exp Therap: 323:1-10.
DC Deecher, P Alfinito, L Leventhal, GH. Johnston, S Cosmi, I Merchenthaler* & R Winneker (2007) Alleviation of
thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in
ovariectomized rodent models. Endocrinology 148(3) 1376-1383.
N Maswood, PD. Alfinito, S Cosmi, L Leventhal, GH Johnston & DC Deecher (2006) Evaluation of the Selective Serotonin
Reuptake Inhibitor, Fluoxetine, in Ovariectomized (OVX) Rat Models of Temperature Regulation. Neuroendocrinology
AC Pawlyk, S Cosmi, PD Alfinito, DC Deecher (2006) Mirtazapine Exerts Multiple Effects on Temperature Regulation in
Ovariectomized Rats. Brain Research 1123 (1): 135-144.
DC Deecher, CE Beyer, G Johnston, J Bray, S. Shah, M. Abou-Gharbia and TH Andree (2006) Desvenlafaxine Succinate: A
New Serotonin and Norepinephrine Reuptake Inhibitor. J Pharm Exp Therapeutics 318:657-665.
PD Alfinito, C Huselton, X Chen and DC Deecher (2006) Pharmacokinetic and pharmacodynamic profiles of the novel
serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats Brain
DC Deecher. 2005. Physiology of thermoregulatory dysfunction and current approaches of treatment for vasomotor
symptoms. Expert Opinion on Investigational Drugs V14 (4) 1-14.
L Leventhal, S Cosmi & DC Deecher (2005) Effect of Calcium Channel Modulators on Temperature Regulation in
Ovariectomized Rats. Pharm Biochem Behav 80 (3) 511-520.
DC Deecher, P Daoud, R Bhat and LT O’Connor (2005). Endogenously expressed estrogen receptors mediate
neuroprotection in a hippocampal cell line (HT22). J Cell Biochem 95 (2): 302-312.
PE Stevis and DC Deecher. (2005) Analysis of glycoprotein hormone receptor extracellular domain interactions using a solid-
phase capture assay. Analytical Biochemistry 338 (2): 320-325.
K Sipe, L Leventhal, K Burroughs, S Cosmi, GH Johnston & DC Deecher (2004) Serotonin 2A Receptor Modulates Tail-Skin
Temperature in Two Rodent Models of Thermoregulatory Dysfunction. Brain Research 1028: 191-202.
PE Stevis*, BJ Arey1, DC Deecher. (2004) A Glutathione-S-Transferase-FSHα subunit hybrid associates with FSHα, retains
biological activity and facilitates purification. BBRC 319:1025-1030.
DC Deecher, P Swiggard, DE Frail & LT O’Connor (2003) Characterization of a membrane estrogen receptor in a rat
hypothalamic cell line (D12) Endocrine 22(3) 211-224.
B.J. Arey, DC Deecher, ES Shen, PE Stevis, J Wrobel, DE Frail & FJ López (2002) Identification and characterization of a
selective, non-peptide follicle-stimulating hormone receptor antagonist. Endocrinology 143(10) 3822-3829.
J Wrobel, D Green, J Jetter, W Kao, J Rogers, M. Claudia Perez, J Hardenburg, DC Deecher, FJ Lopez, BJ Arey and ES Shen
(2002) Synthesis of (bis)Sulfonic Acid, (bis)Benzamides as Follicle-Stimulating Hormone (FSH) Antagonists. Bioorganic
Med. Chem.10: 639-656.
DC Deecher and FJ López (2002) Discrimination of galanin receptor subtypes in RINm5F cells by structurally different galanin
radioligands. Peptides 23: 545-553.
EJ Mufson, DC Deecher, M. Basile, S. Izenwasser and DC Mash. (2000) Galanin receptor plasticity within the Nucleus Basalis
in early Alzheimer’s disease: an in vitro autoradiographic analysis. Neuropharmacology 39(8):1404-1412.
PE Stevis, DC Deecher, L. Suhadolnik, LM Mallis and DE Frail (1999) Differential Effects of Estradiol and Estradiol-BSA
Conjugates. Endocrinology (Rapid Communication) 140(11) 5455-5458.
SL Fitzpatrick, TJ Berrodin, SF Jenkins, DM Sindoni, DC Deecher, DE Frail. (1999) Effect of estrogen agonist and antagonists
on induction of progesterone receptor in a rat hypothalamic cell line. Endocrinology 140(9) 3928-3937.
PE Stevis, DC Deecher, FJ López and DE Frail (1999) Expression and Pharmacological Characterization of the Soluble
Human FSH receptor Extracellular Domain: Facilitated Secretion by FSH. Endocrine 10(2) 153-160.
SL Fitzpatrick, JM Funkhouser, DM Sindoni, PE Stevis, DC Deecher, AR Bapat, I. Merchanthaler, DE Frail. (1999) Expression
of Estrogen Receptor-n Protein in Rodent Ovary. Endocrinology 140(6)2581-2591.
E. J. Mufson, A. Ulrika Kahl, Jeffrey H. Kordower, Robert Bowser, Deborah C. Mash and DC Deecher (1998). Galanin
Expression within the Basal Forebrain In Alzheimer’s Disease: Comments On Therapeutic Potential. Annals of the New
York Academy of Science 863:291-304.
GT Payne, DC Deecher and DM Soderlund (1998) Structure-activity relationships for the action of dihydropyrazole
insecticides on mouse brain sodium channels. Pesti. Biochem. Physiol. 60:177-185.
ES Shen, EH Meade, MC Pérez, DC Deecher, A. Negro-Vilar and FJ López (1998) Expression of functional estrogen
receptors and galanin mRNA in immortalized luteinizing hormone-releasing hormone neurons: Estrogenic control of
galanin gene expression. Endocrinol. 139 (3) 939-948.
DC Deecher, D. C. Mash, J. K. Staley and E. J. Mufson (1998) Characterization and localization of galanin receptors in human
entorhinal cortex. Regulatory Peptides 73:149-159.
B.J Arey, PE Stevis, DC Deecher, ES Shen, D Frail and FJ López. (1997) Induction of promiscuous G-protein coupling of the
FSH receptor: A novel mechanism for transducing pleiotropic actions of FSH isoforms. Mol. Endocrinol 11(5): 517-526.
A.G Schultz, A. Wang, C. Alva, A. Sebastian, S. D. Glick, DC Deecher and J. M. Bidlack. (1996) Asymmetric syntheses,
opioid receptor affinities and antinociceptive effects of 8-amino-5, 9-methanobenzocyclooctenes, a new class of structural
analogues of the morphine alkaloids. J. Med. Chem. 39:1956-1966.
DC Deecher, O. Odusan and E. Mufson. 1995. Galanin receptors in Human Basal Forebrain Differ from receptors in the
hypothalamus: Characterization using [125I] galanin (porcine) and [125I] galantide. J. Pharmacol. Exp. Ther. 275:720-727.
DC Deecher, B. D. Wilcox, P. Conley & H. Kimelberg. 1993. Detection of 5HT2 receptors and 5HT-uptake sites using
radioligand binding, northern blot analysis and Ca2+ in rat primary astrocyte cultures. J. Neuroscience 35: 246-256.
A. Sebastian, J. M. Bidlack, Qi Jiang, DC Deecher, M. Teitler, S. D. Glick & S. Archer. 1993. 14b-[(p-
Nitrocinnamoyl)amino]morphinones, 14b-[(p-Nitrocinnamoyl)amino]-7,8-dihydromorphinones and their codeinone
analogues: Synthesis and receptor activity. J. Med. Chem. 36: 3154-3160.
DC Deecher, M. Teitler & S. D. Glick. 1992. Mechanisms of action Ibogaine and Harmaline based on radiolabeled ligand
binding sites. Brain Research 571: 242-247.
DC Deecher. & D. M Soderlund. 1991. RH 3421, An insecticidal pyrazoline, inhibits sodium channel-dependent sodium uptake
in mouse brain preparations. Pesti. Biochem. & Physio. 39:130-137.
DC Deecher & D. M Soderlund. 1991. Inhibition of sodium channels and [3H]Batrachotoxin A-20-benzoate binding by a
dihyropyrazole neurotoxin. Pesti. Biochem. & Physio. 41: 265-273.
DC Deecher, Payne, G. & D. M. Soderlund. 1991. Mode of action of dihydropyrazoles on sodium channels, in Extended
Summaries Neurotox '91-An International Symposium on the Molecular Basis of Drug and Pesticide Action. Pesti. Sci. 33:
DC Deecher, J. Brezner & S. W. Tanenbaum. 1990. Sublethal effects of Avermectin B1a and Milbemycin D on gypsy moth
(Lepidoptera: Lymantriidae) larvae. J. Econ. Entomol. 83(3): 710-714.
DC Deecher, J. Brezner & S. W. Tanenbaum. 1990. Effects of 4quot;-epi-methylamino-4quot;-deoxyavermectin B1 hydrochloride
(MK-243) on gypsy moth (Lepidoptera: Lymantriidae) larvae. J. Econ. Entomol. 83(3): 917-919.
DC Deecher, J. Brezner & S. W. Tanenbaum. 1989. Effects of abamectin and milbemycin D on the gypsy moth (Lepidoptera:
Lymantriidae). J. Econ. Entomol. 82: 1395-1398.
DC Deecher, J. Brezner & S. W. Tanenbaum. 1987. Avermectin B1a and milbemycin D as contact toxicants for gypsy moth
(Lepidoptera: Lymantriidae) larvae and eggs. J. Econ. Entomol. 80: 1284-1287.
INVITED PEER REVIEWS/BOOK CHAPTERS
DC Deecher 2009 The Pathophysiology of the Thermoregulatory Dysfunction Underlying Menopausal Hot Flashes. Frontiers
in Bioscience Current Issues in Thermal Physiology. American Physiological Society's quot;Handbook of Physiology. Ed. Clark
DC Deecher 2008. Thermoregulation and Menopause: Understanding the Basic Pathophysiology of Vasomotor Symptoms. In
Menopausal Transition: The Interface Between Psychiatry and Gynecology. Eds C. Soares & M. Warren S. Krager AG
DC Deecher 2007. Understanding the Pathophysiology of Vasomotor Symptoms (Hot Flushes and Night Sweats) That Occur
in Perimenopause, Menopause and Postmenopause Life Stages. Archives of Women’s Mental Health 10(6) 247-257.
DC Deecher, T Andree, D Sloan & L Schechter. From menarache to menopause: Exploring the underlying biology of
depression in women experiencing hormonal change (2008) Psychoneuroendocrinology, 33:3-17.
DC Deecher. 2005. Physiology of thermoregulatory dysfunction and current approaches of treatment for vasomotor
symptoms. Expert Opinion on Investigational Drugs V14 (4) 1-14.
SE Counts, SE Perez, U. Kahl, T. Bartfai, R. Bowser, DC Deecher, DC Mash, JN Crawley and EJ Mufson (2001) Neurobiology
of galanin: mechanisms and therapeutic potential for Alzheimer’s Disease. CNS Drug Reviews Vol 7(4): 445-470.
M. Williams, DC Deecher & J. P. Sullivan. 1993. Drug Receptors (Chapter 11). Burger’s Medicinal Chemistry and Drug
Discovery. (Ed. M. E. Wolff) Wiley-Interscience, 5th Edition.
ABSTRACTS SCIENTIFIC MEETINGS (2005-2008; 1989-2004 appendix)
S Cosmi, Pawlyk, PD Alfinito, J Roman, DC Deecher. 2008 Telemetric monitoring of tail-skin and core body temperature in
ovariectomized rats. Society Neuroscience, Nov 08, Washington DC
KD Dave, JA Bray, DC Deecher 2008 Administration of 17β-estradiol to ovariectomized mice reduces anxiety in the marble
burying model. Society Neuroscience, Nov 08, Washington DC
DC Deecher, C Maddage, J Bray, S Cosmi, A Pawlyk, P. Alfinito. 2008 Evaluation of partner preference in a 3-chamber test
box using hormone-primed ovariectomized long evans rats. Int’l Behav Neurosci St. Thomas, June 17-22, 2008
P.D. Alfinito, X. Chen, J. Atherton, X. Ma, DC Deecher 2008. Penetration of the Antiestrogen ICI 182,780 into Brain and
Hypothalamus Tissues of Ovariectomized Sprague-Dawley Rats. Endocrine Society, June 2008 San Francisco, CA
DC Deecher, JN Mason, RJ Richmond, G Stack, PE Mahaney, E Trybulski, RC Winneker, RD Blakely . 2007 Desvenlafaxine
succinate (DVS) identifies novel antagonist binding determinants in the human norepinephrine transporter Society of
Neuroscience, Nov 07 San Diego, CA
PD Alfinito, AC Pawlyk, X Chen, C Stephens, DC Deecher 2007 Estradiol Benzoate Increases Catecholamine Release in the
Hypothalamus of Ovariectomized Rats During the Dark-phase. Society of Neuroscience, Nov 07 San Diego, CA
S Cosmi, C Maddage, J Bray, AC Pawlyk, PD Alfinito, DC Deecher 2007 Assessment of Partner-Preference in a 3-Chamber
Test Box Using Hormone-Primed Ovariectomized (OVX) Long Evans Rats Society of Neuroscience, Nov 07 San Diego,
S Cosmi, C Maddage, J Bray, AC Pawlyk, P Alfinito & DC Deecher. 2007 Assessment of Partner-Preference in a 3-Chamber
Test Box Using Hormone-Primed Ovariectomized (OVX) Long Evans Rats. Society Neuroscience, Nov 06, San Diego, CA
DC Deecher, JN Mason, RJ Richmond, G. Stack, PE Mahaney, E Trybulski, RC Winneker & RD Blakely 2007 Desvenlafaxine
succinate (DVS) identifies novel antagonist binding determinants in the human norepinephrine transporter. Society
Neuroscience, Nov. 6, 2007, San Diego, CA
DC Deecher, PD Alfinito, L Leventhal, S Cosmi, CE Beyer, S Rosenzweig-Lipson, LE Schechter, M Abou-Gharbia, RC
Winneker &TH Andree. 2007 Preclinical Evaluation of Desvenlafaxine Succinate: A New Serotonin and Norepinephrine
Reuptake Inhibitor. Endocrine Society, June 2007 Toronto, CA
AC Pawlyk, G Johnston, PD Alfinito & DC Deecher. 2007 Subchronic Treatment With 17 -Ethinyl Estradiol Suppresses Dark
Phase REM Sleep In Ovariectomized Rats For Up To Six Days. Endocrine Society, June 2007 Toronto, CA
EJ Trybulski, PE Mahaney, LK Gavrin, AT Vu, S Cohn, D Jenkins, J Sabatucci, F Ye, MB. Webb, K Sipe, J Leiter, G Johnston,
K Burroughs, S Cosmi, L Leventhal, Y Zhang, C Mugford, S Rosenzweig-Lipson, B Platt & DC. Deecher Discovery of
Novel and Selective Norepinephrine Reuptake Inhibitors: A Reinvestigation of the Cyclohexanol Ethylamine Scaffold.
American Chemical Society, Sept06, San Francisco, CA
N Maswood, J Bray, DC Deecher. Measurement of female sexual behavior in hormone-primed ovariectomized rats by
partner-prefernce and paced mating paradigms using a video track system. Neuroscience, Oct 06, Atlanta, GA
AC Pawlyk, G Johnston, PD Alfinito, DC Deecher. The effects of repeated administration of 17a-ethinyl estradiol on sleep in
the ovariectomized rat. Neuroscience, Oct 06, Atlanta, GA
AC Pawlyk, S Cosmi, N Maswood, P Alfinito, DC Deecher. Effects of the 5HT2a antagonist mirtazapine in models of
thermoregulation. Neuroscience, Oct 06, Atlanta, GA
PD Alfinito, S Cosmi, X Chen, C Huselton & DC Deecher. Desvenlafaxine succinate (DVS), a new chemical entity, specifically
modulates temperature control in rodent models of thermoregulation. Neuroscience, Oct 06, Atlanta, GA
Navin Maswood , Scott Cosmi, Peter Alfinito, Liza Leventhal & DC Deecher. Evaluation of a selective serotonin reuptake
inhibitor, fluoxetine, on temperature regulation in ovariectomized rat models. Neuroscience, Oct 06, Atlanta, GA
Deecher D, Johnston G, Bray J, Sullivan K andree T and Abou-Gharbia M (2006) In Vitro Profiling of the new serotonin and
norepinephrine reuptake inhibitor desvenlafaxine succinate CINP July 06, Chicago, IL
Deecher D, Beyer CE, Alfinito P, Leventhal L, Cosmi S, Abou-Gharbia M and Winneker R
Restoring Temperature Regulation With The Serotonin And Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate
CINP July 06, Chicago, IL
Andree TH, Rosenzweig-Lipson S, Lin Q, Deecher D, Ludwig B, Dawson LA, Schechter LE, Abou-Gharbia M and Beyer CE
(2006) Preclinical Evidence For Antidepressant And Anxiolytic Efficacy Of The New Dual Serotonin And Norepinephrine
Reuptake Inhibitor Desvenlafaxine Succinate CINP July 06, Chicago, IL
DC Deecher, P Alfinito, G Johnston, S Cosmi, L Leventhal, J Bray, R Winneker (2006) Desvenlafaxine succinate, a new
chemical entity, has potential as a nonhormonal therapy for treatment of vasomotor symptoms. Endocrine Society, June
2006 Boston, MA
DC Deecher, L Leventhal, S Cosmi and N Maswood (2006) Acute effects of serotonin ligands in rat models of ovariectomy-
induced thermoregulatory dysfunction. Endocrine Society June 2006, Boston, MA
DC Deecher, Beyer CE, Alfinito P, Leventhal L, Cosmi S, Abou-Gharbia M and Winneker R (2006) Restoring Temperature
Regulation With The Serotonin And Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate. Endocrine Society June
2006, Boston, MA
T Andree, D Deecher; L Dawson, L Leventhal, K Rogers, P Mitchell, L Schechter, S Rosenzweig-Lipson, C Beyer (2006)
Desvenlafaxine: Preclinical Evidence for Serotonin and Norepinephrine Reuptake Inhibition, Antidepressant and
Antinociceptive Activity. APA, May 2006 Toronto
G. Johnston, Jenifer Bray, T. Andree1 & D. Deecher (2005) Desvenlafaxine succinate: a new serotonin and norepinephrine
reuptake inhibitor. Society of Neuroscience, Washington, DC #268.4
S. Cosmi, N. Maswood, P. Alfinito, C. Huselton2, C.E. Beyer1 & D. Deecher (2005) Desvenlafaxine succinate is a brain
penetrable serotonin and norepinephrine reuptake inhibitor: Pharmacokinetic and neurochemical studies in Sprague-
Dawley rats. Society of Neuroscience, Washington, DC #268.3
P Alfinito, L Leventhal, S Cosmi, I Merchenthaler, R Winneker & D. Deecher (2005) Desvenlafaxine succinate: a selective
serotonin and norepinephrine re-uptake inhibitor restores temperature regulation in two ovariectomy-induced models of
thermoregulatory dysfunction. Society of Neuroscience, Washington, DC #268.2
N. Maswood, J. Bray, P. Alfinito, X. Chen & D. Deecher. (2005) 5-HT2A receptor mediated headshake behavior in male and
female rats. Society of Neuroscience, Washington, DC #871.2
DC Deecher, Liza Leventhal, Scott Cosmi, Grace Johnston, Istvan Merchenthaler & Richard Winneker. (2005) Desvenlafaxine
restores thermoregulatory dysfunction in two preclinical models of temperature regulation. Endocrine Society, San Diego,
PATENT APPLICATIONS (Inventor)
1) Characterization of a membrane estrogen receptor, filed 6/2001’ PCT filed 12/03
2) Methods of treating thermoregulatory disorders: modulation of norepinephrine (NE) levels in combination with
5HT2a receptor antagonist, provisional filed 10/2002, final filed 10/14/03; WO2005/030750
3) Use of norepinephrine reuptake modulators for treating thermoregulatory disorders US2004-0152710A1&
4) Agonism of the 5HT2a receptor for treatment of thermoregulatory dysfunction, provisional filed 9/2002, final filed 9/03
5) Adrenergic alpha2B provisional filed 10/14/03 AM101498 foreign filings (1/05)
6) Novel interaction of venlafaxine-like compounds at the norepinephrine transporter (AM101866)
7) Combinations of NRI and SERM and methods of their Use (AM101823)
8) Triple monoamine transporter inhibitors for the treatment of vasomotor symptoms
2008 Challenges of developing preclinical rodent models of sexual motivation for drug discovery purposes. Symposium:
Translational research on sexual functions: is it possible? Int’l Behav Neurosci St. Thomas, June 18
2007 Drug Discovery Research: “Molecule to Marketplace” Vanderbilt University, Nashville, TN Nov. 30
2006 Pathophysiology of Hot Flushes. American Society of Reproductive Medicine, New Orleans, LA Oct 25
2002 Development of Model Systems to Assess the Role of Estrogens in Neuroprotection. American Aging Association:
Estrogen Neuroprotection: From Molecules to Humans June 10 San Diego, CA
2000 Estrogen in the Brain:A Role in Memory & Cognition. Assoc Women in Science, Phila Chapter, Radnor, PA
1996 Women’s Health Care in the 90’s. Buck’s County Women Business Association, Quakertown, PA
1994 Pharmacology of Cyclic Peptides in Drug Research, SIM, Boston, MA
1991 Receptor pharmacology of anti-addictive drugs. Capital District for Drug Abuse. Albany, NY
1990 Receptor pharmacology of Ibogaine: a treatment for addiction. Capital District for Drug Abuse, Albany, NY
PROFESSIONAL AWARDS & COMMITTEES
2008 quot;Women of the Yearquot; for Contributions to Advancement of Women's Health. Presented at quot;Passion. Purpose
Pathways Luncheon. May 22, Women's Resource Center at Union League, Philadelphia, PA
2008-Learn Team Workshop (2 day)-Content development of all aspects of preclinical research to educate “Wyeth
Learn Team members” responsible for advancing early stage compounds (Ph1&2)
2008-Scientific evaluator Ursinus Competitive Fellowship program projects, Ursinus, Collegeville, PA
2007-2009 Women Leadership Training Program nominated by Executive Committee (1 of 25 selected in R&D)
2007- Regulatory Documentation Optimization Committee to gain Organizational template uniformity (IB, IND, NDA)
2007- Member Senior Leadership Team and governance, Women’s Health
2006- Recognition award for valuable, individual contribution to impact for success of DVS “the molecule” [Pristiq]
2005 Managing for Performance Training Course Fall -Organizer/Coordinator/Presentor
2004-2005 Life cycle management strategy team- Pristiq
2004 Team Leader Initiative Discovery Workshop-Organizer/Coordinator/Presentor
2004 New way of Working at Wyeth in Drug Discovery (content generation, presentation, approval)
2003 External data review, diligence licensing opportunity women’s health indication (March)
2003 Symposium “Female Sexual Dysfunction” Dec. 7-9 (host/organizer/moderator)
2003 Ad-Hoc committee Female Sexual Dysfunction Competitive Landscape Assessment
2003-2005 Co-leader “Drug Discovery the New Way of Working” monthly meetings for Drug Discovery Scientists
2003 New Chemical entity strategy planning committee- menopausal health (Pristiq)
2002-2005 Strategic opportunities assessment 3 -5 year business plan (menopause)
2001 Task force Hit characterization improvement initiative-content design & governance presentation & approval
2000 Special Recognition Award for outstanding contribution to the operations of Wyeth- Ayerst Research
1996-1998 Wyeth content revision on chemical inventory system for Biologists in Discovery
1996-1998 Wyeth Competitive Landscape Awareness member
1996-1998-Wyeth Laboratory Safety member
1995 Wyeth High Throughput Screening planning member
1995-2008 Appointed public relations guided tours for Women’s Health Research
1995-1999 Wyeth appointed Women in Business lecture series
1995 Wyeth Biology job ladder restructuring committee
1993 Science Education Promotional- Commercials for Science Education sponsored by Abbott Labs
1993 Women in Science at Abbott- Lecture series: Career opportunities for Women in Science
1993 Biotechnology Development Committee for assessment of new technologies, Abbott Lab
1993 Receptor Task Force member for lead identification, Abbott Lab
1992 Founder/Coordinator/Presentor Receptor Pharmacology Monthly Luncheon Series, Abbott Lab
1992-1998 Consultant/Evaluator NEN DuPont [125I] radiochemicals
1987 Co-organizer/Presenter, Research by Women in Science, Syracuse University
CONTINUED TRAINING & EDUCATION
2007-2008 Leadership training for Future Women Leaders in R & D at Wyeth (nomination by Executive Committee)
2004-2006 Eagles Leadership training program for top 5% performance in Wyeth R & D (2 year)
2005 Drug Development Training R & D (5 day)
2005 Women Leadership Training for Drug Discovery Research March (2 day)
2002 Drug Development Lecture Series (15 h classroom instruction)
2002 Structure and Function GPCRs: New Opportunities for Commercial Development Philadelphia, PA
2001 “Leading Work Teams” Workshop (2 day)
1995 Public relations speaker and tour guide training (2 day)
SUMMER INTERN/MENTORING PROGRAM
2004- Ciana Hayes- Ursinus College- currently Medical School- Temple, Philadelphia, PA
2002-2003- Margo Montgomery- Villanova College- Currently Medical School Jefferson, Philadelphia, PA
2000- Kaya Jones-Applied to Medical School
2000- Adriene Shey- Completed Graduate School
1996-Maria Seme Nelson-Northwestern University- currently employed by Wyeth, Chazy
1992-1994- Adjunct Instructor. Chicago Medical College, Pharmacology Dept. North Chicago, IL
1983-1988- Instructor. Mohawk Valley Community College, Biology Dept., Utica, NY
1986-1987- Adjunct Instructor. SUNY College of Technology, Biology Dept., Utica, NY
ACTIVE PROFESSIONAL MEMBERSHIPS
Society of Neuroscience (1989)
Endocrine Society (2005)
Revised 3.17.09 DCD